Industry Reports

Momenta Pharmaceuticals, Inc reported its financial results for the second quarter ended June 30, 2016.For the second quarter of 2016, the Company reported total revenues of $26.4 million, including $20.7 million in product revenues from Sandoz's sale of Glatopa®...

Boehringer Ingelheim reported currency-adjusted growth in all its core businesses in the first half of 2016. At the same time, the research-driven pharmaceutical company achieved key strategic milestones by signing contracts to exchange businesses with Sanofi and completing the...

GSK delivers further progress against strategy with strong Q2 performance Group sales £6.5 billion, +4% CER, with growth across all three businesses   -Pharmaceuticals £3.9 billion, +2%; Vaccines £960 million, +11%; Consumer Healthcare, £1.7 billion, +7%...

Merck known as MSD outside the United States and Canada announced that the Board of Directors has declared a quarterly dividend of $0.46 per share of the company’s common stock for the fourth quarter of 2016. Payment will be...

Gilenya (USD 811 million, +17% cc) continued to grow double-digit mainly due to volume growth Cosentyx (USD 260 million) grew strongly driven by its three approved indications Core operating income declined (-4% cc) due...

Gilead Sciences, Inc  announced that its second quarter 2016 financial results will be released on Monday, July 25, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial...

Johnson & Johnson today announced that its Board of Directors has declared a cash dividend for the third quarter of 2016 of $0.80 per share on the company’s common stock. The dividend is payable on September 6, 2016 to...